To Sign the NDA
Copy and paste the link below into your web browser:

https://generational.tfaforms.net/4660083?DealID=a1L2G000005Ycqa

REVENUE / EBITDA

2025 Revenue (Proj.) - $900K

2025 EBITDA (Proj.) - $127K

2024 Revenue - $591K

2024 EBITDA - $(166K)


BUSINESS HIGHLIGHTS

The Company, established in 2011 to bring a proprietary therapy to the region, is a specialized treatment center focused exclusively on degenerative disc conditions. The treatment is a patented, FDA-cleared (though non-invasive) treatment designed to restore disc health by repairing a degenerated disc's internal "pump mechanism" to restart self-healing. The treatment has a 98% success rate in achieving significant improvement and durable relief, as validated by two independent, randomized medical studies.

Unlike typical care options that focus on symptoms (e.g., physical therapy, epidural injections, surgery), this method addresses the root cause of disc degeneration.

Customers and Markets. The Company treats conditions including sciatica, degenerative disc disease, spinal stenosis, bulging/herniated discs, and related symptoms such as pinched nerves or annular tears.

The Company serves thousands of clients with a program cost of approximately $7,500 to $11,000, 100% private pay.


The Company’s fixed assets include devices, equipment, office furniture, and leasehold improvements, among other items. Management believes the facilities and equipment are in good condition and will support future growth.

Conditions Treated. The treatment targets root causes of the following spinal conditions, with the goal to restore disc health and alleviate symptoms:

There is no pain during treatment, no side effects, and no need to take downtime or recovery time off of work.

INVESTMENT APPEAL

Management Will Remain Through Transition. Ownership is willing to remain with the Company after a transaction to facilitate an orderly transition to new ownership.

Strong Client Relationships. The Company has built an extensive client list and good industry relationships since its inception.

Facilities Will Support Pro Forma Growth. The Company’s facility and resources are not currently at capacity, so future growth will be supported by the current assets and facilities on hand.

Outstanding Growth Opportunities. Several opportunities exist for the Company to significantly increase revenue and profit, including leveraging the Company’s proven reputation to pursue and penetrate new and existing markets. These opportunities are easily attainable given the appropriate investments in capital and human resources.

Modest Ongoing Capital Investment Requirements. The Company has very modest ongoing capital expenditures. To support pro forma growth, only modest annual capital investment of $5,000 is required, with a 3% growth rate in order to reach the pro forma sales figures.

EXPERIENCED TEAM

8 Part-Time

The practice has been set up to allow the Doctor to work a hybrid scenario, which includes days working remotely and days working in-office.